Let's not forget that many of these patients went through 3

New Post Public Reply Private Reply Replies (5) Message Board
Respert24 Katangolo #153043
823
Let's not forget that many of these patients went through 3 or 4 lines of treatment before they got to try Leronlimab. I'm reminded of the Einstein covid patients that were the worst of the worst, including transplant patients. And while only a few lived, every one of them showed an immune response from LL. Sadly some had too much to overcome, and I think it's very likely a strong handful of these breast cancer patients were in a similar boat. At some point you're going to have a difficult time reversing cancer, and maybe some of these patients had a very small window that 350 couldn't overcome, but 700 could have. Or neither were going to work due to progression of the disease, or a unique metabolic makeup that just simply wouldn't respond.

I'm super excited about the survival data and am looking forward to the crc trial filling, the next step in mTNBC, a (very likely) partner getting on board to infuse cash and awareness, and also glio. I think the second attempt at glio was likely informed heavily by the survival and moa analysis that was shaking out as they set about giving glio a second look. I'm hopefuly that they are able to show a through-line across crc/basket, mTNBC, and glio because if they can show any substantial effect in glio there's always a chance of the coveted emergency approval. I would love some sort of accelerated approval of LL for mTNBC, but there are a lot of treatments already that have some effect, even if it isn't as good as what we now believe LL can do when paired with an ICI. But with glio there aren't many options and the disease hits fast and hard. Let's all cross our fingers AND DOUBLE EVERY ELEVEN that this glio redo is outstanding. It'll help build Cytodyn's worth for partnerships and buyouts, but more importantly it could end up meaning extended life for some of the most brutal cancers a person can be diagnosed with.

Lastly, I think it's important I reiterate that you should ALWAYS double eleven. Always. Trust me. I was once approached by Stuey Ungar, who was probably the best poker player who ever lived. He fought demons and lived a much shorter life than he should have, otherwise he'd be a household name. But while he was alive we got to know each other in Biloxi while fleecing locals in secret underground games. He saw the spark in my eye and the quality of my play, deciding it was smarter to pair up and teach me his ways lest I overtake him, leaving him floundering in my wake with nothing.

So he taught me about probability, and how I can use things like VPIP to my advantage, shaping my game to where I was unstoppable. We hit Vegas and I was crushing everything from the Omaha Hi-Lo NL to Razz and everything in between. I got banned from many casinos, but not for my play. They were concerned I was too handsome and distracting the cocktail waitresses. I, of course, was tipping liberally on every bottle of Opus One I ordered (daily drinker back then) and they were hovering over me like dancers at an otherwise empty strip club.

But I flew a little too close to the sun and had to switch to blackjack for reasons I won't go into. But the last thing Stu said to me was, "Always double your elevens. Always." This was shortly after his unexpected comeback win at the World Series of Poker in 1997. Years later I was gifted his book before it was published because I was a prolific poker writer, the publisher hilariously unaware that he was my mentor. It was an amazing read, but heartbreaking too. But then I noticed that if you took the first letter of each chapter and laid them out, it spelled "DOUBLE YOUR ELEVENS" and I nodded to the heavens. Message received, pal. Message received.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 11

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 7

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 7

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 11

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 4

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 10

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 6

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 10

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 5

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

Chart Industries Transitions to New Leadership in Upcoming Merger

Updated Category News Views 231

Chart Industries Announces Leadership Change Chart Industries (NYSE: GTLS) is taking significant steps toward a future transition as CEO Jill Evanko has announced plans to assume a senior advisor role starting in early 2026. This change comes as she prepares to take on a new executive opportunity within a privately owned company. Evanko has been essential in steering the...

Continue Reading
Understanding Debtors: Insights into Realkredit Danmark A/S

Updated Category News Views 299

Understanding Debtors: Key Insights from Realkredit Danmark A/S At the heart of any effective financial institution is a reliable understanding of its debtors. Realkredit Danmark A/S, a prestigious name in the financial landscape, recently made available a detailed breakdown of its debtors. This information is crucial for various stakeholders, including investors,...

Continue Reading
Cryptocurrency Market Update: Bitcoin Droops under $59K with ETF Inflows Soaring

Updated Category News Views 148

Bitcoin's Recent Performance The cryptocurrency market has been lively lately, especially with Bitcoin recently falling below the $59,000 threshold. Investors had been optimistic, especially since the cryptocurrency saw a remarkable $436 million in net ETF inflows just last week. This significant influx signals that institutional interest in cryptocurrencies is still...

Continue Reading
Enhancing Specialized Care for ARFID Treatment with Emily Program

Updated Category News Views 169

Introduction to The Emily Program and ARFID The Emily Program is making significant strides in specialized care for individuals with Avoidant/Restrictive Food Intake Disorder (ARFID). This condition, often misunderstood, has recently begun to garner more attention from healthcare experts. In response to this need, The Emily Program is offering advanced treatment...

Continue Reading
Investigation of Alleged Securities Fraud at 3D Systems Unfolds

Updated Category News Views 167

Overview of Legal Actions Against 3D Systems Corporation Recently, investors in 3D Systems Corporation have found themselves entangled in a potential securities fraud lawsuit. This case serves as a cautionary tale, highlighting the importance of transparency and integrity in corporate communication. The allegations stem from assertions that the company made misleading...

Continue Reading